About Event

There is increased investment in gene therapies to treat hemophilia, sickle cell disease and β-thalassemia, however developing these programs pose unique indication-specific challenges. Understanding the specific challenges and opportunities in this space is crucial to ensure the success of your gene therapy program.

This focused agenda brings together key thought leaders across the blood disease space to share their expertise at every stage of clinical and commercial development, including:

  • Gene Editing Innovators
  • Clinical Developers
  • Patient Advocacy Experts
  • Commercial Launch Leaders
  • Market Access Strategists

Companies confirmed to present their insights into these key topics include:

bluebird bio
Spark Therapeutics
Pfizer
uniQure
Sanofi
Sigilon
Catalyst Biosciences
Editas
Poseida
CRISPR
LogicBio
NHF

Download the full event guide to find out more.